KRAS modulators
Novel KRAS inhibitors, represented by compounds of Formula (I) and its variants, address the challenge of targeting KRAS mutations in cancer, achieving effective inhibition of KRAS protein activity and providing a promising therapeutic option for cancer treatment.
WO2025064542A1 Publication Date: 2025-03-27ALTEROME THERAPEUTICS INC
13 Cites 21 Cited by
Patent Information
- Application Number
- PCT/US2024/047282
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-07-15
- Filing Date
- 2024-09-18
- Publication Date
- 2025-03-27
AI Technical Summary
Technical Problem
There is an unmet need for novel compounds that can effectively inhibit KRAS protein, which is often implicated in cancer and neoplastic diseases but was previously considered 'undruggable'.
Method used
The development of specific KRAS inhibitors, represented by compounds of Formula (I), (Ia), (Ib), (Ic), and (Id), or their pharmaceutically acceptable salts or solvates, which target various mutations such as G12C, G12D, and G12V, thereby disrupting KRAS signaling pathways.
Benefits of technology
These compounds demonstrate the potential to effectively inhibit KRAS protein activity, offering a therapeutic approach for treating cancer and neoplastic diseases by targeting previously hard-to-reach mutations.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided herein are inhibitors of KRAS, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the KRAS inhibitory compounds for the treatment of diseases or disorders.
Need to check novelty before this filing date? Find Prior Art